S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Biden's Plan to Confiscate Your Cash? (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Sell every Stock except ONE (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Sell every Stock except ONE (Ad)
NYSE:USNA

USANA Health Sciences - USNA Stock Forecast, Price & News

$69.16
+0.17 (+0.25%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$68.11
$69.47
50-Day Range
$65.12
$76.51
52-Week Range
$63.49
$103.95
Volume
46,296 shs
Average Volume
66,296 shs
Market Capitalization
$1.33 billion
P/E Ratio
15.23
Dividend Yield
N/A
Price Target
$77.33

USANA Health Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
11.8% Upside
$77.33 Price Target
Short Interest
Bearish
4.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$225,450 Sold Last Quarter
Proj. Earnings Growth
8.54%
From $3.98 to $4.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

875th out of 1,135 stocks

Medicinals & Botanicals Industry

10th out of 14 stocks

USNA stock logo

About USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 26th. Jefferies Financial Group lowered shares of USANA Health Sciences from a "hold" rating to an "underperform" rating and lowered their price objective for the stock from $78.00 to $53.00 in a research report on Thursday, July 7th. Finally, DA Davidson reduced their target price on shares of USANA Health Sciences to $57.00 and set an "outperform" rating for the company in a research report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $77.33.

USANA Health Sciences Stock Up 0.2 %

USNA traded up $0.17 during trading hours on Friday, hitting $69.16. The stock had a trading volume of 46,296 shares, compared to its average volume of 66,296. USANA Health Sciences has a 1 year low of $63.49 and a 1 year high of $103.95. The company's fifty day simple moving average is $70.54 and its 200 day simple moving average is $77.42. The stock has a market cap of $1.33 billion, a PE ratio of 15.23 and a beta of 0.72.

USANA Health Sciences (NYSE:USNA - Get Rating) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.05). USANA Health Sciences had a net margin of 8.27% and a return on equity of 22.49%. During the same quarter in the prior year, the business posted $1.87 earnings per share. As a group, equities analysts expect that USANA Health Sciences will post 3.98 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other news, insider Brent Neidig sold 1,400 shares of the firm's stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $70.93, for a total value of $99,302.00. Following the completion of the transaction, the insider now directly owns 1,406 shares of the company's stock, valued at $99,727.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Brent Neidig sold 1,400 shares of the company's stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $70.93, for a total transaction of $99,302.00. Following the sale, the insider now directly owns 1,406 shares in the company, valued at $99,727.58. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO G Doug Iiekking sold 1,086 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $70.51, for a total transaction of $76,573.86. Following the completion of the transaction, the chief financial officer now owns 1,838 shares of the company's stock, valued at $129,597.38. The disclosure for this sale can be found here. Insiders have sold 3,202 shares of company stock valued at $225,450 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Stock News Headlines

Expert Ratings for Usana Health Sciences
USANA Health Sciences Continues To Fall
USANA Legal Team Brings Home Two Awards
Kevin Guest Promotes World Day of Music
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Company Calendar

Last Earnings
7/26/2022
Today
8/14/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,978
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.33
High Stock Price Forecast
$122.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
+11.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$116.50 million
Pretax Margin
12.47%

Debt

Sales & Book Value

Annual Sales
$1.19 billion
Cash Flow
$7.13 per share
Book Value
$21.03 per share

Miscellaneous

Free Float
19,129,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
0.72














USNA Stock - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price forecast for 2022?

3 brokers have issued 1-year price objectives for USANA Health Sciences' stock. Their USNA share price forecasts range from $53.00 to $122.00. On average, they anticipate the company's stock price to reach $77.33 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2022?

USANA Health Sciences' stock was trading at $101.20 at the beginning of the year. Since then, USNA stock has decreased by 31.7% and is now trading at $69.16.
View the best growth stocks for 2022 here
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, July, 26th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.05 by $0.05. USANA Health Sciences had a trailing twelve-month return on equity of 22.49% and a net margin of 8.27%. During the same quarter in the prior year, the business earned $1.87 EPS.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 9th 2021, which authorizes the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 8.2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of $1.05-$1.05 for the period, compared to the consensus EPS estimate of $1.26. The company issued revenue guidance of $265.00 million-$265.00 million, compared to the consensus revenue estimate of $272.77 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.46%), Pzena Investment Management LLC (3.78%), Northern Trust Corp (0.64%), JPMorgan Chase & Co. (0.44%), Principal Financial Group Inc. (0.40%) and Nordea Investment Management AB (0.40%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $69.16.

How much money does USANA Health Sciences make?

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.33 billion and generates $1.19 billion in revenue each year. The company earns $116.50 million in net income (profit) each year or $4.54 on an earnings per share basis.

How many employees does USANA Health Sciences have?

The company employs 1,978 workers across the globe.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.

This page (NYSE:USNA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.